Holen Sie sich die Stockscreener-App
21.57
0.12%
-0.07
Handel nachbörslich:
21.58
0.010
+0.05%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt FMS?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$21.64
Offen:
$21.96
24-Stunden-Volumen:
639.93K
Relative Volume:
0.98
Marktkapitalisierung:
$11.59B
Einnahmen:
$22.18B
Nettoeinkommen (Verlust:
$1.36B
KGV:
11.23
EPS:
1.9216
Netto-Cashflow:
$2.00B
1W Leistung:
-2.19%
1M Leistung:
-5.07%
6M Leistung:
-9.26%
1J Leistung:
-25.52%
1-Tages-Spanne:
$21.55
$21.96
1-Wochen-Bereich:
$21.55
$22.59
52-Wochen-Spanne:
$20.02
$29.71
Fresenius Medical Care Ag Adr Stock (FMS) Company Profile
Firmenname
Fresenius Medical Care Ag Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare FMS vs HCA, THC, DVA, EHC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FMS
Fresenius Medical Care Ag Adr
|
21.58 | 11.62B | 22.18B | 1.36B | 2.00B | 1.9216 |
HCA
Hca Healthcare Inc
|
392.52 | 87.42B | 76.39B | 7.81B | 7.93B | 29.08 |
THC
Tenet Healthcare Corp
|
176.41 | 14.97B | 21.46B | 2.65B | 3.35B | 19.23 |
DVA
Davita Inc
|
195.71 | 12.74B | 13.84B | 1.10B | 1.49B | 10.42 |
EHC
Encompass Health Corp
|
104.93 | 10.41B | 6.07B | 793.80M | 464.40M | 5.9914 |
Fresenius Medical Care Ag Adr Stock (FMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-20 | Herabstufung | Goldman | Buy → Neutral |
| 2025-10-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-09-02 | Herabstufung | UBS | Neutral → Sell |
| 2024-12-02 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-11-06 | Eingeleitet | Berenberg | Buy |
| 2024-01-08 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-11-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-17 | Hochstufung | Societe Generale | Hold → Buy |
| 2023-08-14 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Fortgesetzt | Citigroup | Neutral |
| 2023-07-12 | Eingeleitet | Goldman | Buy |
| 2023-03-07 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-01-03 | Herabstufung | Jefferies | Buy → Underperform |
| 2022-10-26 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-10-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-06-27 | Hochstufung | Jefferies | Underperform → Buy |
| 2022-02-11 | Herabstufung | Jefferies | Hold → Underperform |
| 2021-11-23 | Eingeleitet | HSBC Securities | Hold |
| 2021-11-11 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-02-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2020-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2020-05-20 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2020-01-21 | Hochstufung | Jefferies | Hold → Buy |
| 2019-06-20 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-12-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-26 | Hochstufung | UBS | Neutral → Buy |
| 2018-08-28 | Hochstufung | HSBC Securities | Hold → Buy |
| 2018-07-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-01-04 | Hochstufung | UBS | Sell → Neutral |
| 2017-12-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2016-11-01 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2016-09-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2016-07-08 | Hochstufung | Jefferies | Underperform → Hold |
| 2016-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2015-11-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2015-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2015-08-13 | Herabstufung | Societe Generale | Buy → Hold |
| 2015-07-31 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2013-08-02 | Bestätigt | Feltl & Co. | Hold |
| 2013-01-14 | Hochstufung | HSBC Securities | Neutral → Overweight |
Alle ansehen
Fresenius Medical Care Ag Adr Aktie (FMS) Neueste Nachrichten
Fresenius Medical Care announces €1 billion share buyback program - Investing.com
Fresenius Medical Care at the 63rd ERA Congress - Fresenius Medical Care
Fresenius Medical Care announces new share buyback program with a total volume of around EUR 1 billion with phased execution over 12 months - Fresenius Medical Care
Research in Brief: Online hemodiafiltration and medium cut-off dialyzers - Fresenius Medical Care
Fresenius Medical Care stock (DE0005785802): Dividend vote and guidance shape the 2026 setup - AD HOC NEWS
Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care - Fresenius Medical Care
Fresenius Medical Care stock (DE0005785802): New focus on dialysis demand and margin discipline - AD HOC NEWS
Fresenius Medical Care reappoints CFO Martin Fischer until 2031 - Investing.com
Fresenius Medical Care Reappoints Chief Financial Officer Martin Fischer - Morningstar
Fresenius Medical Care stock (DE0005785802): earnings update and strategy focus - AD HOC NEWS
Fresenius Medical Care stock (DE0005785802): dialysis specialist in focus after latest quarterly upd - AD HOC NEWS
Fresenius Medical Care stock (DE0005785802): New dialysis trends keep the company in focus - AD HOC NEWS
Ready4 Ci-Ca: Innovation in clinical education - Fresenius Medical Care
Fresenius Medical Care: Shares Look Attractive, Despite Market Uncertainty Around Margin Trajectory - Morningstar
Fresenius Medical Care AG (FMS) Stock Price, Trades & News - GuruFocus
Fresenius SE & Co. KGaA stock (DE0005785604): Global healthcare giant with US dialysis exposure - AD HOC NEWS
Fresenius Medical Care stock (DE0005785802): Dialysis giant faces headwinds and opportunities in 202 - AD HOC NEWS
Fresenius Medical Care Q1 2026 slides: margin expansion amid revenue pressures - Investing.com Australia
Fresenius Medical Care Q1 2026 slides: margin expansion amid revenue pressures By Investing.com - Investing.com South Africa
Fresenius Medical Care's Margin Improvement Looks Just Paused in 2026, Not Over - Morningstar
Earnings call transcript: Fresenius Medical Care Q1 2026 beats EPS expectations - Investing.com
Fresenius Medical Care Q1 shares fall on U.S. treatment slowdown - Investing.com
Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed - Fresenius Medical Care
Fresenius Medical Care stock (DE0005785802): Is chronic kidney disease demand strong enough to unloc - AD HOC NEWS
Fresenius Medical Care stock (DE0005785802): Why Google Discover changes matter more now - AD HOC NEWS
Fresenius Medical Care stock (DE0005785802): Is U.S. dialysis dominance still the key growth engine? - AD HOC NEWS
Fresenius Medical Care stock (DE0005785802): Why U.S. dialysis demand now drives the real value test - AD HOC NEWS
Fresenius Medical Care stock (DE0005785802): Is U.S. dialysis dominance still the key growth lever? - AD HOC NEWS
Research in Brief: Immunosuppressive therapies in kidney transplant recipients - Fresenius Medical Care
Fresenius Medical Care Sets May 21, 2026 AGM With Dividend and New Buyback Mandate on Agenda - TipRanks
Fresenius Medical Care (NYSE: FMS) plans €1.49 dividend and renews 10% buyback mandate - Stock Titan
Fresenius Medical Care stock: What you should know now before buying - AD HOC NEWS
Supporting living donors through the Circle of Excellence - Fresenius Medical Care
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now - Zacks Investment Research
Fresenius Medical Care stock advances FME Reignite strategy with Interwell Health investment amid st - AD HOC NEWS
10 New 5-Star Stocks This Week - Morningstar
Fresenius Medical Care publishes its Annual Report 2025: The power of care - Fresenius Medical Care
Research round-up: Innovation that moves kidney care forward - Fresenius Medical Care
Advancing kidney care: Introducing high-volume hemodiafiltration to the U.S. - Fresenius Medical Care
Fresenius Medical Care Faces a Transition Year in 2026 on New Product Launch Activities - Morningstar
Fresenius Medical Care marks World Kidney Day and National Kidney Month - Fresenius Medical Care
Fresenius Medical Care's 2030 Ambition: Navigating a Pivotal Transition () - aktiencheck.de
Fresenius Medical Care: An Undervalued Stock to Buy Now and Hold for the Long Term - Morningstar
5 Undervalued Stocks That Crushed Q4 Earnings - Morningstar
FMS Stock Rises as Q4 Earnings & Sales Beat Estimates, Margins Expand - Finviz
Research in Brief: Nocturnal home hemodialysis - Fresenius Medical Care
Fresenius Medical Care ADR earnings beat by $1.11, revenue topped estimates - Investing.com Australia
Fresenius Medical Care published Report on Form 20-F for fiscal year 2025 - Fresenius Medical Care
Fresenius Medical Care Q4 2025 slides: margin surge, flat 2026 outlook - Investing.com
Earnings call transcript: Fresenius Medical Care Q4 2025 beats EPS expectations - Investing.com
Fresenius Medical Care falls nearly 7% despite earnings beat - Investing.com South Africa
Finanzdaten der Fresenius Medical Care Ag Adr-Aktie (FMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):